Page results
-
The diagnostic haematology clinics at UCLH perform comprehensive blood testing, including blood film examination, immunophenotyping and molecular testing.
-
The UCLH children’s FGC/M clinic provides specialist care for children and adolescents who have undergone or are at risk of FGC/M.
-
A drop-in service providing support, practical advice and information.
-
A team of clinician scientists at UCLH have identified the factors which predict full hearing recovery, with the strongest predictor being treatment with steroids within seven days of a sudden drop in hearing.
-
This information explains radium-223 therapy treat available at University College Hospital.
-
This page aims to help you decide if a post-dates induction of labour is the right decision for you and your baby.
-
The UCLH Maternity Voices Partnership (MVP) is a team of women and their families, commissioners and providers (midwives and doctors) working together to review and contribute to the development of local maternity care.
-
UCLH has received excellent results in the 2023 National Adult Inpatient Survey this year, with patients rating their overall care 8.8 out of 10. This is an improvement on last year's score of 8.7 and once again makes us the best performing acute/combined trust in England.
-
Paediatric Audio-vestibular Medicine provides investigation, diagnosis and management of the medical aspect of disorders of hearing, balance and tinnitus in children. The service consists of a multi-professional team and is located at The Royal National ENT & Eastman Dental Hospitals, 47-49 Huntley Street London WC1E 6DG.
-
This page provides information about an interventional procedure called an Epidural Fibrin Patch. It is intended for use by patients (or their family or carers), who have been referred to the NHNN.
File results
-
FOI/2024/0361 - Recording RTT waiting times: Planned patients guidance
-
FOI/2024/0360 - Radiology Information System (RIS) supplier/ contract/ staff details
-
FOI/2024/0357 - Multiple myeloma treatments
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0513 - Robotic platforms for surgery costs/ contract
-
FOI/2024/0512 - Patient harm and the cost 2020-2023
-
FOI/2024/0511 - Radiotherapy treatment planning system/artificial intelligence (AI)/ costs
-
FOI/2024/0514 - Viscosupplementation injections/ spend